AU2002232407A1 - Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof - Google Patents

Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof

Info

Publication number
AU2002232407A1
AU2002232407A1 AU2002232407A AU3240702A AU2002232407A1 AU 2002232407 A1 AU2002232407 A1 AU 2002232407A1 AU 2002232407 A AU2002232407 A AU 2002232407A AU 3240702 A AU3240702 A AU 3240702A AU 2002232407 A1 AU2002232407 A1 AU 2002232407A1
Authority
AU
Australia
Prior art keywords
fortilin
tctp
modulators
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002232407A
Inventor
Kenichi Fujise
Edward Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002232407A1 publication Critical patent/AU2002232407A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
AU2002232407A 2000-10-30 2001-10-30 Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof Abandoned AU2002232407A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24441600P 2000-10-30 2000-10-30
US60/244,416 2000-10-30
PCT/US2001/042985 WO2002036624A2 (en) 2000-10-30 2001-10-30 Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof

Publications (1)

Publication Number Publication Date
AU2002232407A1 true AU2002232407A1 (en) 2002-05-15

Family

ID=22922671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002232407A Abandoned AU2002232407A1 (en) 2000-10-30 2001-10-30 Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof

Country Status (3)

Country Link
US (1) US7691567B2 (en)
AU (1) AU2002232407A1 (en)
WO (1) WO2002036624A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177692A1 (en) * 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
WO2003097835A2 (en) * 2002-05-16 2003-11-27 Molecular Engines Laboratories Pharmaceutical compositions for the treatment of cancer
US20030233118A1 (en) * 2002-06-13 2003-12-18 Hui John C. K. Method for treating congestive heart failure using external counterpulsation
WO2004065572A2 (en) * 2003-01-23 2004-08-05 Molecular Engines Laboratories Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
EP1636383B1 (en) * 2003-06-21 2016-11-23 Ewha University Industry Collaboration Foundation Composition for screening anti-hypertension drug comprising mammal tctp gene or its protein product, and method for screening anti-hypertension drug using said composition
WO2005005983A1 (en) * 2003-07-14 2005-01-20 Japan Science And Technology Agency Method of diagnosing disease relating to endometriosis
JP4564926B2 (en) * 2005-01-25 2010-10-20 エワ ユニバーシティ−インダストリー コラボレーション ファウンデーション Deletion IgE-dependent histamine-releasing factor having histamine secretion ability, HRF-binding peptide and method of using the same
US8050774B2 (en) 2005-12-22 2011-11-01 Boston Scientific Scimed, Inc. Electrode apparatus, systems and methods
US7840281B2 (en) 2006-07-21 2010-11-23 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
FR2919060B1 (en) * 2007-07-19 2012-11-30 Biomerieux Sa METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919061B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919064B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF ASSAYING APOLIPOPROTEIN ALL FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
WO2009019368A2 (en) * 2007-07-19 2009-02-12 bioMérieux Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer
FR2919065B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD FOR DETERMINING APOLIPOPROTEIN AI FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919063B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING LEUCOCYTE ELASTASE INHIBITOR FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919062B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING AMINOACYLASE 1 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
FR2933773B1 (en) * 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
KR101036854B1 (en) 2008-08-19 2011-05-25 재단법인서울대학교산학협력재단 Polypeptide for inducing apoptosis, dna encoding same and a pharmaceutical composition for inducing apoptosis containing same
US9034840B2 (en) * 2010-12-17 2015-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
WO2012166579A1 (en) * 2011-05-31 2012-12-06 Fox Chase Cancer Center Synergistic inhibition of erbb2/erbb3 signal pathways in the treatment of cancer
KR101837735B1 (en) * 2016-08-08 2018-04-19 성균관대학교산학협력단 Composition containing translationally controlled tumour protein for oocytes’s anti-aging or improving of oocyte’s fertility
WO2024059471A2 (en) * 2022-09-12 2024-03-21 University Of Washington Small molecular weight inhibitors of fortilin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO1994012881A2 (en) * 1992-12-02 1994-06-09 Hochstrasser Denis F A METHOD FOR DETECTING GROWING CELLS USING TRANSLATIONALLY CONTROLLED TUMOR PROTEIN p21
US5763263A (en) * 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948639A (en) * 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
US6228586B1 (en) * 1998-01-30 2001-05-08 Genoplex, Inc. Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
EP1212354A2 (en) 1999-09-10 2002-06-12 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US20020102532A1 (en) * 2000-10-03 2002-08-01 Meena Augustus Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
WO2002036624A2 (en) 2002-05-10
US20030172388A1 (en) 2003-09-11
WO2002036624A3 (en) 2002-08-29
WO2002036624A9 (en) 2003-11-20
US7691567B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
AU2002232407A1 (en) Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof
AU2002337953A1 (en) Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
AU2002315052A1 (en) Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
AU2002307797A1 (en) Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses
AU2001292842A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002350079A1 (en) Gel composition and methods of use
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002339904A1 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2001252917A1 (en) 7 human ovarian and ovarian cancer associated proteins
AU2001297741A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU2002217991A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002357382A1 (en) Compositions and methods relating to endometrial specific genes and proteins
AU2001297804A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002253946A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002236579A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002241557A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.
AU2002331780A1 (en) Compositions and methods relating to lung specific genes and proteins
AU2001268087A1 (en) Compositions and methods for modulating tumor specific expression
AU2002335686A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2003228331A1 (en) Dry feeling low spreading emollient gel
AU2002364105A1 (en) Compositions and methods relating to endometrial specific genes and proteins
AU2002332760A1 (en) Compositions and methods relating to ovary specific genes and proteins